A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants

Description

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.

A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of VX-407 in Healthy Subjects

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants

Condition
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention / Treatment

-

Contacts and Locations

Lenexa

ICON Lenexa, Lenexa, Kansas, United States, 66219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
  • * A total body weight of greater than (\>) 50 kg
  • * Nonsmoker or ex-smoker for at least 3 months before screening
  • * History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
  • * Any condition possibly affecting drug absorption

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Vertex Pharmaceuticals Incorporated,

Study Record Dates

2025-04